Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

News|Videos|July 27, 2023

Experts Present Background on Long-Term Safety Study of Upadacitinib for AD

Author(s)Ruth Ann Vleugels, MD, MPH, MBA, Christopher G. Bunick, MD, PhD

Christopher Bunick, MD, PhD, introduces an integrated analysis of phase three studies analyzing the long-term safety of upadacitinib as treatment for atopic dermatitis (AD). He also highlights a burgeoning standard to assess the safety of treatment.

Episodes in this series

EP. 1 JAK Inhibitor Overview and Relevance to AD

EP. 1 JAK Inhibitor Overview and Relevance to AD

EP. 2 Comparing Current Treatment Agents for AD

EP. 2 Comparing Current Treatment Agents for AD

EP. 3 Clinical Experience With JAK Inhibitor in AD

EP. 3 Clinical Experience With JAK Inhibitor in AD

EP. 4 Experts Present Background on Long-Term Safety Study of Upadacitinib for AD

EP. 4 Experts Present Background on Long-Term Safety Study of Upadacitinib for AD

EP. 5 Experts on Results of Long-Term Safety Study of Upadacitinib for AD

EP. 5 Experts on Results of Long-Term Safety Study of Upadacitinib for AD

EP. 6 Conclusions of Study on Long-Term Safety Study of Upadacitinib for AD

EP. 6 Conclusions of Study on Long-Term Safety Study of Upadacitinib for AD

EP. 7 Assessing Risk Factors of Oral JAK Inhibitors and Traditional Agents

EP. 7 Assessing Risk Factors of Oral JAK Inhibitors and Traditional Agents

EP. 8 Experts Present Background on JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 8 Experts Present Background on JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 9 Experts on Results of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 9 Experts on Results of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 10 Visualizing Safety Rates: Drug Events, Disease Baseline, and General Population Baseline

EP. 10 Visualizing Safety Rates: Drug Events, Disease Baseline, and General Population Baseline

EP. 11 Box Warning and JAK Inhibitor

EP. 11 Box Warning and JAK Inhibitor

EP. 12 JAK Inhibitor Selectivity

EP. 12 JAK Inhibitor Selectivity

EP. 13 Conclusions of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 13 Conclusions of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 14 Evolving the Standard of Care for AD: Safety and Treatment Response

EP. 14 Evolving the Standard of Care for AD: Safety and Treatment Response

EP. 15 Transitioning Patients from Traditional Immunosuppressive Agents to JAK Inhibitor

EP. 15 Transitioning Patients from Traditional Immunosuppressive Agents to JAK Inhibitor

EP. 16 AD Endotypes and Outcomes

EP. 16 AD Endotypes and Outcomes

EP. 17 Final Thoughts on JAK Inhibitor for AD

EP. 17 Final Thoughts on JAK Inhibitor for AD

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

New Consensus Defines Remission, Disease Activity in Atopic Dermatitis

ByShannon Heaning, Content Associate

July 20th 2026

ED Treatment Gaps Persist for Pediatric Atopic Dermatitis

ByChristopher G. Bunick, MD, PhD,Shannon Heaning, Content Associate

July 18th 2026

Precision Medicine in Atopic Dermatitis: Current Challenges and Future Directions

ByChristopher G. Bunick, MD, PhD,Shannon Heaning, Content Associate

July 15th 2026

Soficitinib (ICP-332) Meets Primary Endpoint in Phase 3 Trial for Moderate to Severe AD

ByMarie Bosslett, Assistant Editor

July 15th 2026

Skin & Psych: Addressing Psychological Stress in Pediatric Atopic Dermatitis Care

ByPatricia Delgado, DNP, AGPCNP, DCNP, PMHNP,Peter Lio, MD,Shannon Heaning, Content Associate

July 14th 2026

Latest CME

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis

New Consensus Defines Remission, Disease Activity in Atopic Dermatitis

Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites

Beyond Retinol: Evaluating the Stability, Safety, and Gene-Expression Profile of Bakuchiol Ferulate

AI-Assisted Imaging Tracks Success of Low-Fluence QSRL Laser for Melasma